A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.

NCT07058662

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Belief BioMed (Beijing) Co., Ltd
Enrollment	9 participants

Key Eligibility Criteria

Inclusion (9)

- The Participants and/or his legal guardian must fully understand the purpose, nature, methods, and potential risks of the study, and sign a written informed consent form.
- Ambulatory male subjects aged 4 years and above but under 9 years (4 years d age \< 9 years).
- Any mutation in the DMD gene confirmed by genetic testing
- Serum creatine kinase (CK) during the screening period meets the study requirements.
- Receiving stable, standard-dose glucocorticoids before screening.

... and 4 more (see full listing online)

Exclusion (12)

- Positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV-DNA) e 1000 U/mL, hepatitis C virus ribonucleic acid (HCV-RNA) positive, human immunodeficiency virus (HIV) positive, or positive for Treponema pallidum antibodies.
- Currently receiving antiviral therapy for hepatitis B, hepatitis C, HIV, etc.
- The investigator deems the subject has severe behavioral or cognitive disorders that may hinder participation in this study.
- Poorly controlled asthma, or Duchenne Muscular Dystrophy (DMD) leading to significant decline in lung function, or recurrent infectious pneumonia that the investigator considers may affect respiratory function.
- Left ventricular ejection fraction (LVEF) \< 50% or New York Heart Association (NYHA) cardiac function class e III.

... and 7 more (see full listing online)

Locations (1 total)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China